Differential mechanisms of bicalutamide-induced apoptosis in prostate cell lines

Prostate Cancer and Prostatic Diseases

Volumn 12, Issue 1, 2009, Pages 25-33

  St John Floyd Jr , M ^a   Teahan, S J ^a   Fitzpatrick, J M ^a   Watson, R W G ^a  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; BICALUTAMIDE; CALPAIN; CALPAIN 2 INHIBITOR; CASPASE; ENZYME INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESEARCH; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RESEARCH; ENZYME INHIBITION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

ANILIDES; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FLOW CYTOMETRY; HUMANS; MALE; NITRILES; PROSTATE; PROSTATIC NEOPLASMS; TOSYL COMPOUNDS;

EID: 60349100648     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2008.23     Document Type: Article

References (25)

1. Saad F. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol 2002; 29 (6 Suppl 21): 19-27.
2. Blackledge G. Casodex - mechanisms of action and opportunities for usage. Cancer 1993; 72 (12 Suppl): 3830-3833.
3. Anderson J. The role of antiandrogen monotherapy in the treatment of prostate cancer. BJU Int 2003; 91: 455-461.
4. Lekas E, Bergh A, Damber JE. Effects of finasteride and bicalutamide on prostatic blood flow in the rat. BJU Int 2000; 85: 962-965.
5. Nickerson T, Pollak M. Bicalutamide. (Casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology 1999; 54: 1120-1125.
6. Culig Z, Hoffmann J, Erdel M, Hobisch A, Hittmair A, Bartsch G. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 1999; 81: 242-251.
7. Madarova J, Lukesova M, Hlobilkova A, Rihakova P, Murray PG, Student V. Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide. Neoplasma 2001; 48: 419-424.
8. Zhan P, Lee EC, Packman K, Tenniswood M. Induction of invasive phenotype by casodex in hormone-sensitive prostate cancer cells. J Steroid Biochem Mol Biol 2002; 83: 101-111.
9. Kerr JF, Wyllie AH, Currie AR. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 1972; 26: 239-257.
10. Hetts SW. To die or not to die: An overview of apoptosis and its role in disease. JAMA 1998; 279: 300-307.
11. Berner C, Monney L. Apoptosis without caspases: An inefficient molecular guillotine? Cell Death Differ 1999; 6: 497-507.
12. Masiello D, Cheng S, Bubley GJ, Lu LM, Balk SP. Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor. J Biol Chem 2002; 277: 26321-26326.
13. Lee EC, Zhan P, Schallhom R, Packman K, Tenniswood M. Antiandrogen-induced cell death in LNCaP human prostate cancer cells. Cell Death Differ 2003; 10: 761-771.
14. Chen CD, Welsbie DS, Tran C, Back SH, Chen R, Vasella T et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
15. Berges RR, Vukanovic J, Epstein JI, Carmichel M, Cisek L, Johnson DE et al. Implication of cell kinetic changes during the progression of human prostatic cancer. Clin Cancer Res 1995; 1: 473-480.
16. Denis L, Mahler C. Pharmacodynamics and pharmacokinetics of bicalutamide: Defining an active dosing regimen. Urology 1996; 47 (LA suppl): 26-28.
17. Vicentini C, Festuccia C, Angelucci A, Gravina GL, Muzi P, Eleuterio E et al. Bicalutamide dose dependently inhibits proliferation in human prostatic carcinoma cell lines and primary cultures. Anticancer Res 2002; 22: 2917-2922.
18. Li X, Marani M, Mannucci R, Kinsey B, Andriani F, Nicoletti I et al Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells. Cancer Res 2001; 61: 1699-1706.
19. Carafoli E, Molinari M. Calpain: A protease in search of a function? Biochem Biophys Res Commun 1998; 247: 193-203.
20. Wood DE, Newcomb EW. Caspase-dependent activation of calpain during drug-induced apoptosis. J Biol Chem 1999; 274: 8309-8315.
21. Mamoune A, Luo JH, Lauffenburger D, Wells A. Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res 2003; 63: 4632-4640.
22. Zhang H, Hoff H, Sell C. Downregulation of IRS-1 protein in thapsigargin-treated human prostate epithelial cells. Exp Cell Res 2003; 289: 352-358.
23. Zhu DM, Uckun FM. Calpain inhibitor II induces caspase-dependent apoptosis in human acute lymphoblastic leukemia and non-Hodgkin's lymphoma cells as well as some solid tumor cells. Clin Cancer Res 2000; 6: 2456-2463.
24. Lu Q, Mellgren RL. Calpain inhibitors and serine protease inhibitors can produce apoptosis in HL-60 cells. Arch Biochem Biophys 1996; 334: 175-181.
25. Bouchal J, Baunforth KNR, Svachova MM, Murray PG, Von Angerer E, Kolar Z. Microarray analysis of bicalutamide action on telomerase activity, p53 pathway and viability of prostate carcinoma cell lines. J Pharm Pharmacol 2005; 57: 83-92.